drugset
drugset / Trial / NCT01660022

Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects

NCT01660022 ↗

Phase 1 Completed 59 enrolled Medicines for Malaria Venture Cross Research S.A. · collab
RandomizedCrossoverQuadruple-blindBasic science

Summary

A Phase I Study to investigate the safety, tolerability \& pharmacokinetics of co-administered single doses of OZ439 and Piperaquine to healthy subjects.

Timeline

Start
2012-09
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Artefenomel Small molecule 100 mg Oral
Subject Artefenomel Small molecule 300 mg Oral
Subject Artefenomel Small molecule 800 mg Oral
Subject piperaquine Small molecule 160 mg Oral
Subject piperaquine Small molecule 480 mg Oral
Subject piperaquine Small molecule 1440 mg Oral

Indications

No indication recorded.